

1 Information about the Patient Advocacy Group

Name of the drug and indication(s):

Tafinlar & Mekinist in combo for Melanoma

Name of registered patient advocacy group: Save Your Skin Foundation

Contact person: Kathleen Barnard

Title: President/Founder

Phone: 604-985-1999

Email: kathy@saveyourskin.ca


1.1 Information Gathering

Please briefly identify how the information to complete Sections 2 and 3 was obtained. Was it obtained, for example, through personal experience, surveys, focus groups, one-to-one conversations with a number of patients using current therapy, printed sources, etc?

Information obtained to complete Sections 2 came from one on one interview's with a number of late stage melanoma patients some of which have gone through the treatment under review. Section 3 came from interviews with patients that have undergone the treatment under review only.

1.2 Confirmation of Authorship

I have the authority to declare this patient advocacy group has sole authorship of this submission and to confirm that no other parties have written or participated in the writing of the submission.



Signature

2015/03/02

Date (YYYY/MM/DD)

2 Condition and Current Therapy Related Information

1.3 Experience Patients Have with This Type of Cancer

The diagnosis of cancer impacts all aspects of patients' lives. Furthermore, different cancers, and stages of cancer, affect patients in different ways. Recognizing this, the focus of the information requested in this section relates to the impact of the cancer for which the drug under review is indicated. What are the symptoms and problems associated with this cancer that impact a patient's day-to-day life and quality of life? Examples of the type of information that could be included are:

- Which aspects (e.g., cough, pain, edema, appearance) of this cancer are more important to control than others?
- How do ongoing symptoms affect day-to-day life?
- Describe any limitations as a result of the cancer.

The aspects of melanoma that are more important to control than others are pain from tumour growth and the pain from those tumours on the patients body especially in areas of movement (legs arms etc). The scars from surgery to remove tumours greatly impact the physical appearance of the patient

Ongoing symptoms from patients included loss on energy, fear, anxiety and depression. All of the patients experienced moderate to sever emotional distress. Some patients suffered fatigue, mood swings, vitality and low energy levels.

Limitations included are the inability to mentally and physically return to work, the inability to return to "normal" daily life, and anxiety and depression due to their prognosis, therefore unable to continue to work. Patients have also suffered from loss of mobility due to muscle and tissue removal of surgery or treatment.

Problems with surgery if tumour is in a difficult location on the body

Realizing that there are now treatments available to patients but they are not always recommended by their oncologist or administered in their hospital.

1.4 Patients' Experience with Current Therapy

How well are patients managing their disease with currently available treatments?

Examples of the types of information that might be included are:

- What therapies are patients using to treat this type of cancer?
- How effective is the current therapy in controlling the common aspects of this cancer, e.g., pain, fatigue?
- What are common adverse effects and are some more difficult to tolerate than others?
- Would patients be willing to tolerate potential adverse effects resulting from treatment, if the benefits were only short-term?

- Are there hardships in accessing current therapy? Can patients readily access available treatments in their own communities?
- In addition to the drug cost, are there other financial implications to patients or caregivers (e.g., traveling costs, drug disposal issues, drug administration supplies)?
- Are there needs, experienced by some or many patients that are not being met by current therapy? What are these needs?

Current drugs used to treat melanoma are Interferon, surgery, radiation, Decarbazine(DTIC), Temozolomide, Stereotactic Radiation(used on brainstem tumours) Zelboraf, Yervoy, Trametinib, Dabrafenib.

Few positive results recorded with any of the patients interviewed that underwent Interferon, DTIC, Temozolomind. Patients experienced fatigue and pain from the cancer while undergoing treatment regimes using these therapies. Patients felt these treatments probably slowed the spread of disease, but were not effective in preventing metastasis.

Adverse side effects that were difficult to tolerate; extreme fatigue, diarrhea, skin issues, nausea, rash, low sodium levels, colitis. Many side effects have been so severe that patients have not been able to perform daily functions.

Newer therapies are becoming more readily available not don't work for all patients and take time to get to. Patients feel frustrated as time is very important when dealing with Melanoma and sometimes it is months before treatments are available.

90% of the patients responded "yes" that they would "try anything" to win their fight with this cancer. The other 10% responded, "yes" depending on the severity of the side of effects.

Other financial implications involved unemployment i.e. patients could not work while being administered the drugs and have to travel to specific centres for treatment

Needs that are not being met are the lack of treatments for Melanoma patients in a timely fashion. Current therapies have a better survival rate but getting the right patient to the right treatment in the right centers are big issues.

Many patients were not offered newer treatment options from their oncologist and were disappointed that there was no unified melanoma protocols across the country.

Many melanoma patients are still dying because there are still not enough treatment options available in a timely fashion. There is also concern that their needs are not being met and that their issues are not being heard.

1.5 Impact on Caregivers

What challenges do caregivers face in caring for patients with this type of cancer? How do treatments impact a caregiver's daily routine or lifestyle? Are there challenges in dealing with adverse effects related to the current therapy?

For this section, a number of caregivers who had a close family member who was diagnosed with melanoma were interviewed:

The emotional distress due to an uncertain prognosis and unknown treatment plan, cancellation of any long-term plans, and time away from work to assist the patient all impacted the routine of the caregiver.

The challenge for the caregiver was confusion over the effects related to the current therapy. The caregivers interviewed found it difficult to know if the symptoms were treatment or cancer related. Lack of information about the side effects was noted by the caregivers, resulting in confusion and distress.

The main challenge for some caregivers was finding treatments that might work for the loved one. They cost to the family to travel to centers for treatment is very difficult. Time away from family while getting treatment was an issue

3 Related Information about the Drug Being Reviewed

3.1 What Are the Expectations for the New Drug or What Experiences Have Patients Had To Date with the New Drug?

- How much improvement in the condition would be considered adequate with this drug compared with current drug therapy?
- Is it expected that the lives of patients will be improved by this drug, and how?
- Is there a particular gap or unmet patient need in current therapy that this drug will help alleviate?
- What are the potential risks associated with the drug and do they outweigh the benefits?
- What other benefits might this drug have—for example, fewer hospital visits or less time off work?

There is a large, unmet need for melanoma in Canada. There still hasn't been enough advancement in the treatment of melanoma. It took over 30 years for patient to get treatments with a better survival rate than the older, current therapies with very low survival rates. Patients interviewed are willing to have any type of treatment to survive. All patients agreed that we need more treatment options for this type of cancer for chances of survival. Patients feel they all respond to different treatments and are hoping this will be the one that extends their survival or in some ways extends their survival till they find the treatment that works for them.

The most common side effect of all patients was fatigue. Some patients had fever and flu like symptoms (chills, cough and headache) and a very few patients interviewed had mild nausea. All patients agreed that all adverse effects were acceptable and that the drug was as easy to use as other treatments.

The negative effect is that it takes a long time to know if the treatment works.

With all patients interviewed the benefits outweigh the risks of the drug. Symptoms seem to be as tolerable as current therapies and hopefully it increases the overall survival rate of a patient with melanoma.

Some patients interviewed were disappointed that they had to find this treatment themselves and that they had to travel outside their provinces to obtain the treatment. They also felt that if they had received this treatment sooner the end result might have been better for them.

Based on patients' experiences with the drug as part of a clinical trial or through a manufacturer's compassionate supply or by paying for it out of pocket or through private insurance:

- What positive and negative effects does the drug have on the disease?
- Which symptoms does the drug manage better than the existing therapy and which ones does it manage less effectively?
- Does the drug cause adverse effects?
- Which adverse effects are acceptable and which ones are not?
- Is the drug easier to use?
- How is the drug expected to change patients' long-term health and well-being?

Positive effects for some patients had a complete response to date and the complete disappearance of all signs of cancer. Other patients interviewed had other tumours appear and will now need new treatment options.

All patients reported symptoms of fatigue, mild flu like symptoms, like fever and chills but agreed they were manageable. All patients were monitored closely by their oncologists.

None of patients interviewed showed any severe side effects to treatment. But when asked were willing to go to extreme lengths to work thru any side effects as they still felt treatment options are not readily available for patients.

All patients understood when undergoing treatment that data did not show long term survival but were still willing to have treatment administered.

4 Additional Information

Please provide any additional information that would be helpful to pCODR. This could include suggestions for improving the patient input process, indicating whether the questions are clear, etc.

Some of patients interviewed had to leave their province to have their treatment. The expenses of travelling away from family and to other provinces was extremely stressfully emotionally and financially.